Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. R33 supports Phase II of an exploratory/developmental Grant. 

Funding: $300,000 per year

Duration: 3 years

Research Authority due date: 10 days prior to submission

LOI (encouraged) due date: 21.1.20, 28.4.20, 29.8.20

Full proposal due date: 21.2.20, 28.5.20, 29.9.20